Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir

AIDS

Volumn 30, Issue 5, 2016, Pages 761-769

  Calin, Ruxandra ^a,b,c   Hamimi, Chiraz ^b   Lambert Niclot, Sidonie ^a,b   Carcelain, Guislaine ^b   Bellet, Jonathan ^b   Assoumou, Lambert ^b   Tubiana, Roland ^a,b   Calvez, Vincent ^a,b   Dudoit, Yasmine ^a,b   Costagliola, Dominique ^b,c   Autran, Brigitte ^b,c   Katlama, Christine ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ORVACS   (France)

Author keywords

chronic HIV infection; HIV cure; HIV reservoir; posttreatment controller; treatment interruption

Indexed keywords

ABACAVIR; ATAZANAVIR; CD4 ANTIGEN; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EMTRICITABINE; ETRAVIRINE; HLA B27 ANTIGEN; HLA B35 ANTIGEN; HLA B57 ANTIGEN; LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANALYTIC METHOD; ANALYTIC TREATMENT INTERRUPTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HETEROSEXUALITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LONG TERMINAL REPEAT; LYMPHADENOPATHY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; MYALGIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; ADOLESCENT; AGED; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROVIRUS; TREATMENT WITHDRAWAL; VIREMIA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROVIRUSES; VIRAL LOAD; VIREMIA; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84963657822     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000987     Document Type: Article

References (26)

1. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. Lancet Lond Engl 2013; 382: 1515-1524
2. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4R T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-517
3. Quesada PR, Esteban LL, García JR, Sánchez RV, García TM, Alonso-Vega GG, et al. Incidence and risk factors for tenofovirassociated renal toxicity in HIV-infected patients. Int J Clin Pharm 2015; 37: 865-872
4. D Ascenzo F, Cerrato E, Biondi-Zoccai G, Moretti C, Omedè P, Sciuto F, et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-Analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J 2012; 33: 875-880
5. Li JZ, Smith DM, Mellors JW. The critical roles of treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS Lond Engl 2015; 29: 1429-1432
6. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296
7. Colven R, Harrington RD, Spach DH, Cohen CJ, Hooton TM. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 2000; 133: 430-434
8. Bouldouyre M-A, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, et al. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial. J Acquir Immune Defic Syndr 2009; 1999: 2009; 52: 531-537
9. Tubiana R, Ghosn J, De-Sa M, Wirden M, Gautheret-Dejean A, Bricaire F, et al. Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission. AIDS Lond Engl 2002; 16: 1083-1084
10. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41: 1053-1056
11. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS Lond Engl 2000; 14: 123-131
12. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-Treatment HIV-1 controllers with a long-Term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: e1003211
13. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T-W, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369: 1828-1835
14. Ananworanich J, Puthanakit T, Suntarattiwong P, Chokephaibulkit K, Kerr SJ, Fromentin R, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS Lond Engl 2014; 28: 1015-1020
15. Frange P, Faye A, Avettand-Fenoel V, Bellaton E, Deschamps D, Angin M, et al. HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child [Oral Abstract MOAA0105LB]. 8th IAS Conference on HIV Pathogenesis, 19-22 July 2015, Vancouver, Canada
16. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee T-H, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014; 161: 319-327
17. AssoumouL, Weiss L, Piketty C, BurgardM, MelardA, Girard P-M, et al.AlowHIV-DNAlevel inperipheral bloodmononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS Lond Engl 2015; 29: 2003-2007
18. Haïm-Boukobza S, Morand-Joubert L, Flandre P, Valin N, Fourati S, Sayon S, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS Lond Engl 2011; 25: 341-344
19. Avettand-Fènoël V, Chaix M-L, Blanche S, Burgard M, Floch C, Toure K, et al. LTR real-Time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81: 217-223
20. Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and posttreatment virological control. eLife 2014; 3: e03821
21. Li JZ, Heisey A, Ahmed H, Wang H, Zheng L, Carrington M, et al. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS Lond Engl 2014; 28: 2649-2657
22. Yerly S, Günthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, et al. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS Lond Engl 2004; 18: 1951-1953
23. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 2003; 188: 1426-1432
24. Magierowska M, Theodorou I, Debré P, Sanson F, Autran B, Rivière Y, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-Term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999; 93: 936-941
25. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix M-L, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PloS One 2008; 3: e3907
26. International HIV Controllers Study. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330: 1551-1557